Novavax Analyst Says COVID-19 Vaccine Could Net $400M In Yearly Sales
Novavax Analysts Say CEPI Funding 'Speaks Volumes' About Coronavirus Vaccine Development
Biotech Stock On The Radar: vTv Therapeutics's Diabetes Pipeline
Abeona Therapeutics Has First-Mover Potential In Rare Diseases, Seaport Says In Bullish Initiation